Gilead Sciences Outperforms Broader Market as Institutional Stakes Shift
Gilead Sciences shares have reached record levels following quarterly earnings that topped forecasts. Despite recent executive share sales and institutional rebalancing, Wall Street maintains a Moderate Buy consensus.
Institutional investors continue to adjust their holdings in Gilead Sciences, Inc. following a strong rally that pushed the stock to all-time highs. Recent regulatory filings show Allspring Global Investments Holdings LLC reduced its stake in the biopharmaceutical company by 33.6% in the third quarter, offloading 153,043 shares while maintaining 303,098 shares worth $44,707,000. Conversely, Elite Wealth Management Inc. boosted its position by 171.5% over the same timeframe, acquiring 26,129 shares.
The institutional portfolio adjustments follow quarterly financial results reported on October 29th that surpassed Wall Street projections. Gilead generated $2.55 in earnings per share, exceeding analyst expectations of $2.19. Quarterly revenue advanced 6.8% year over year to $8.30 billion, topping the projected $7.81 billion. While profitability metrics showed a net loss margin of 12.47% and an equity return deficit of 1.85%, core operations gained traction after removing COVID-19 therapy Veklury, whose revenue plunged 69% to $86 million in the September quarter.
Excluding Veklury, the company recorded an underlying quarterly growth rate of 16%, driven by an 18% increase in HIV product revenue and a 13% rise in liver disease drug sales. Oncology revenues advanced 9%. Backed by clinical momentum, including positive one-year persistence data for twice-yearly HIV prevention drug lenacapavir and primary biliary cholangitis trial results for Livdelzi, management lifted full-year guidance and maintained its quarterly dividend of $0.82 per share.
Meanwhile, corporate insiders executed scheduled divestments. Chief Executive Officer Daniel O'Day sold 102,619 shares on November 4th and 9,810 shares on November 5th at an average price of $175.17, retaining 551,683 shares. These trades were conducted through a pre-arranged Rule 10b5-1 trading plan.
Yahoo Finance reported that Gilead shares have advanced 38% since the beginning of the year, outperforming the S&P 500's 10% gain. Wall Street sentiment remains largely favorable. MarketBeat tracks an average consensus rating of Moderate Buy across 29 analysts, alongside an average target price of $170.15, with individual firm targets ranging from $127.00 to $196.00.